search
Back to results

Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE (MAYBE)

Primary Purpose

Sarcopenic Obesity, Frailty, Malnutrition; Protein

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
AA-1
AA-2
Placebo
Exe-H
Sponsored by
Azienda Ospedaliera Universitaria Integrata Verona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcopenic Obesity

Eligibility Criteria

60 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Participants will be included in the study based on the following inclusion criteria: Older men and women between 60-80 years The presence of sarcopenic obesity was considered when the following two conditions were satisfied: Fat mass > 34.8% and FFM <90% of subject's ideal FFM. Resident in Verona (Italy) Stable weight in the previous 2 months Previously sedentary (less than one hour of exercise per week in the last 6 months) Signing of the informed consent for participation in the study Exclusion criteria: Unstable angina or recent myocardial infarction Malignant or unstable arrhythmias Heart failure NYHA class > II Severe respiratory failure Severe heart valve disease (i.e severe aortic stenosis or insufficiency) Abdominal and/or thoracic aneurysm Recent intracerebral or subdural haemorrhage Poorly controlled arterial hypertension Presence of pacemakers or metal prostheses Severe chronic renal failure Symptomatic musculoskeletal pathology Symptomatic disc herniation, arthrosis, acute joint, tendon and ligamentous injuries, hip and/or knee prostheses recently placed (<6 months) or with joint instability, symptomatic or large inguinal or abdominal hernia Acute retinal detachment or bleeding Recent eye surgery (laser, cataract, retinal surgery, glaucoma surgery) History of malignant cancer within the previous 5 years Diagnosis of dementia Eating disorders

Sites / Locations

  • AOUI Verona

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Exe-H + placebo

Exe-H + AA-1

Exe-H + AA-2

Arm Description

high intensity physical exercise combined with placebo

high intensity physical exercise combined with low dose of aminoacids

high intensity physical exercise combined with high dose of aminoacids

Outcomes

Primary Outcome Measures

Change from baseline 1-repetition maximum with isokinetic dynamometer at 5-months
Change in 1-repetition maximum test performed with isokinetic dynamometer in Kilograms

Secondary Outcome Measures

Change from baseline Short Physical Performance Battery at 5-months
Change in Short Physical Performance Battery Score
Change from baseline in handgrip at 5-months
Change in upper limb muscle strength measured with handgrip in kilograms
Changesfrom baseline skeletal muscle mass at 5-months
Change skeletal muscle mass measured with DXA in kilograms
Change from baseline fat mass at 5-months
Change fat mass measured with DXA in kilograms
Change from baseline in mRNA at 5-months
Change mRNA dosage
Change from baseline in muscle power at 5-months
Change in isokinetic muscle power of the lower limbs in kilograms

Full Information

First Posted
February 21, 2020
Last Updated
July 3, 2023
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Collaborators
Università degli Studi di Brescia, Azienda Ospedaliera di Padova, University of Milan
search

1. Study Identification

Unique Protocol Identification Number
NCT05938205
Brief Title
Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE
Acronym
MAYBE
Official Title
Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
July 6, 2022 (Actual)
Study Completion Date
July 6, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Collaborators
Università degli Studi di Brescia, Azienda Ospedaliera di Padova, University of Milan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will be conducted in a group of obese sarcopenic patients (Sarco-Ob) aged > 60 years on moderately hypocaloric diet therapy aimed at comparing the effect of a strength exercise protocol, combined or not with dietary supplementation with amino acids, on physical performance, muscle strength, body composition, muscle oxidative metabolism, and biomarkers of sarcopenia. The supplementation study will be conducted in a double-blind manner.
Detailed Description
In this double-blind randomised control trial, older men, and women resident in Verona (Italy) will be selected from the Geriatrics Nutritional Clinic of the Borgo Trento Hospital or were contacted by telephone. A specific medical screening was initially programmed to verify the criteria of recruitment. Anthropometric and body composition In the morning, in a fasted state, body mass will be taken with an electronic scale (Tanita electronic scale BWB-800 MA) and stature will be measured with a Harpenden stadiometer (Holtain Ltd., Crymych, Pembs. UK); BMI will be calculated as weight (kg)/height (m)2. Thereafter, total and regional body composition will be evaluated by means of dual-energy X-ray absorptiometry (DXA) using a total body scanner (QDR Horizon W, Hologic, MA, USA; fan-bean technology, software for Windows XP version 12.4.2) according to the manufacturer's procedures. Furthermore, the ALMI will be calculated as the sum of lean mass of arms and legs divided by height squared. Physical performance On the same day, the SPPB test will be used to assess functional performance of the lower extremities. Each participant will performed: 4 m at usual customary gait speed, a five repeated chair-stands test and three standing balance tests (side by side, semi-tandem and tandem). A digital dynamometer (CAMRY, Digital Hand Dynamometer model: EH101) will be used to assess HGS and all measurements were conducted by the same operator. Before starting, participants will observe a demonstration of the test procedure and engage in two practice attempts. Knee muscle strength measurements and analysis An isokinetic dynamometer (CMSi Cybex Humac Norm Dynamometer, Lumex, Ronkokoma, NY, USA) will be used to assess the isokinetic strength of knee flexors and extensors muscles. Maximal isokinetic knee extension-flexion tests will be performed in a randomised sequence at 60, 90, 150, 180 and 210°ˑs-1. Trials will consist in three knee extension-flexion movements with 60 s-recovery. The maximal strength of knee extensors muscle will be calculated with the Hill's hyperbolic function. The isokinetic knee extension-flexion power will be calculated as the product between strength and velocity. Finally, for knee extensors, maximal muscle power expressed in Watt, will be calculated from the power-velocity curve. 1-RM assessment Before starting training intervention, participants will perform three sessions of familiarization with the resistance isotonic machines. High intensity strength exercise (Exe-H) protocol: All the participants will performed a supervised progressive resistance training protocol, three times per week, 1 hour per session. Each participant will performed the same strength training protocol, starting with 3 sets of 8-10 repetitions at 70% of 1-RM (month 1), with a progressive increase of intensity at 75% of 1-RM (month 2 and month 3), and 80% 1-RM that will be maintained for the rest period of intervention. The compliance will be define as the number of exercise sessions expressed in % of the target value. Each participant will must reach a compliance above the 70% to be included in the final analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenic Obesity, Frailty, Malnutrition; Protein

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-center open-label randomized experimental study with 3 parallel arms with an allocation ratio of 1:1:1. Participants will be all involved in high intensity exercise (Exe-H). Participants will be further randomized into 3 groups to receive (double-blind) dietary supplementation with either placebo, low dose amino acid blend (AA-1) or full dose amino acid blend (AA-2).
Masking
ParticipantInvestigator
Masking Description
Double blind
Allocation
Randomized
Enrollment
111 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exe-H + placebo
Arm Type
Experimental
Arm Description
high intensity physical exercise combined with placebo
Arm Title
Exe-H + AA-1
Arm Type
Experimental
Arm Description
high intensity physical exercise combined with low dose of aminoacids
Arm Title
Exe-H + AA-2
Arm Type
Experimental
Arm Description
high intensity physical exercise combined with high dose of aminoacids
Intervention Type
Dietary Supplement
Intervention Name(s)
AA-1
Intervention Description
low dose aminoacids
Intervention Type
Dietary Supplement
Intervention Name(s)
AA-2
Intervention Description
high dose aminoacids
Intervention Type
Behavioral
Intervention Name(s)
Placebo
Intervention Description
Nutritional Placebo
Intervention Type
Behavioral
Intervention Name(s)
Exe-H
Intervention Description
high intensity physical exercise
Primary Outcome Measure Information:
Title
Change from baseline 1-repetition maximum with isokinetic dynamometer at 5-months
Description
Change in 1-repetition maximum test performed with isokinetic dynamometer in Kilograms
Time Frame
Month0, Month5
Secondary Outcome Measure Information:
Title
Change from baseline Short Physical Performance Battery at 5-months
Description
Change in Short Physical Performance Battery Score
Time Frame
Month0, Month 5
Title
Change from baseline in handgrip at 5-months
Description
Change in upper limb muscle strength measured with handgrip in kilograms
Time Frame
Month0, Month5
Title
Changesfrom baseline skeletal muscle mass at 5-months
Description
Change skeletal muscle mass measured with DXA in kilograms
Time Frame
Month0, Month5
Title
Change from baseline fat mass at 5-months
Description
Change fat mass measured with DXA in kilograms
Time Frame
Month0, Month5
Title
Change from baseline in mRNA at 5-months
Description
Change mRNA dosage
Time Frame
Month0, Month5
Title
Change from baseline in muscle power at 5-months
Description
Change in isokinetic muscle power of the lower limbs in kilograms
Time Frame
Month0, Month5

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Participants will be included in the study based on the following inclusion criteria: Older men and women between 60-80 years The presence of sarcopenic obesity was considered when the following two conditions were satisfied: Fat mass > 34.8% and FFM <90% of subject's ideal FFM. Resident in Verona (Italy) Stable weight in the previous 2 months Previously sedentary (less than one hour of exercise per week in the last 6 months) Signing of the informed consent for participation in the study Exclusion criteria: Unstable angina or recent myocardial infarction Malignant or unstable arrhythmias Heart failure NYHA class > II Severe respiratory failure Severe heart valve disease (i.e severe aortic stenosis or insufficiency) Abdominal and/or thoracic aneurysm Recent intracerebral or subdural haemorrhage Poorly controlled arterial hypertension Presence of pacemakers or metal prostheses Severe chronic renal failure Symptomatic musculoskeletal pathology Symptomatic disc herniation, arthrosis, acute joint, tendon and ligamentous injuries, hip and/or knee prostheses recently placed (<6 months) or with joint instability, symptomatic or large inguinal or abdominal hernia Acute retinal detachment or bleeding Recent eye surgery (laser, cataract, retinal surgery, glaucoma surgery) History of malignant cancer within the previous 5 years Diagnosis of dementia Eating disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elena Zoico, PhD
Organizational Affiliation
Universita di Verona
Official's Role
Study Director
Facility Information:
Facility Name
AOUI Verona
City
Verona
ZIP/Postal Code
37126
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.aovr.veneto.it/web/healthyaging/chi-siamo
Description
Healthy Aging Center Verona web site

Learn more about this trial

Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE

We'll reach out to this number within 24 hrs